Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study

Fig. 1

Flow chart presenting the selection process of the study population. Patients with type 2 diabetes newly using SLGT2 inhibitors were selected from the Korean National Health Insurance Service database. Dapagliflozin users were 1:1 matched to empagliflozin users using propensity score matching. SGLT2 sodium-glucose co-transporter 2

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840